The Systemic Candidiasis drugs in development market research report provides comprehensive information on the therapeutics under development for Systemic Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Systemic Candidiasis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Systemic Candidiasis and features dormant and discontinued products.
GlobalData tracks 17 drugs in development for Systemic Candidiasis by 17 companies/universities/institutes. The top development phase for Systemic Candidiasis is preclinical with seven drugs in that stage. The Systemic Candidiasis pipeline has 17 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Systemic Candidiasis pipeline products market are: Profem, Oryn Therapeutics and Cisen Pharmaceutical.
The key targets in the Systemic Candidiasis pipeline products market include Lanosterol 14 Alpha Demethylase, 1,3 Beta Glucan Synthase, and Prostaglandin G/H Synthase 1.
The key mechanisms of action in the Systemic Candidiasis pipeline product include Lanosterol 14 Alpha Demethylase Inhibitor with three drugs in Phase III. The Systemic Candidiasis pipeline products include eight routes of administration with the top ROA being Oral and four key molecule types in the Systemic Candidiasis pipeline products market including Small Molecule, and Synthetic Peptide.
Systemic Candidiasis overview
Systemic candidiasis encompasses a range of yeast infections resulting from various species of Candida, presenting a severe threat that can impact diverse areas of the body such as the blood, heart, brain, eyes, bones, and other organs. While there are over 200 Candida species, five specific types contribute to 90% of systemic candidiasis cases. The primary manifestation of this invasive yeast infection occurs when Candida infiltrates the bloodstream, leading to candidemia. Indications of candidemia include persistent fever and chills unresponsive to antibiotics. Symptoms of other forms of Systemic candidiasis vary depending on the affected organ or system. Particularly prevalent among hospitalized individuals in high-income countries, including the US, systemic candidiasis poses diagnostic challenges, especially when Candida is not detected in the bloodstream.
For a complete picture of Systemic Candidiasis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
